| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.jubilantpharmova.com | |
| Market Cap | 10,602.55 Cr. | |
| Enterprise Value(EV) | 13,048.25 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 2.38 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 280.05 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 40.73 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 343.01 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 1.94 | Calculated using Price: 665.65 |
| Dividend Yield | 0.75 | Period Ending 2023-03 |
| No. of Shares Subscribed | 15.93 Cr. | 159,281,139 Shares |
| FaceValue | 1 | |
| About Jubilant Pharmova Ltd. | ||
| Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals. Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US. | ||
| 1 Day |
|
-5.13% |
| 1 Week |
|
+2.56% |
| 1 Month |
|
+16.75% |
| 3 Month |
|
+19.98% |
| 6 Month |
|
+62.73% |
| 1 Year |
|
+110.45% |
| 2 Year |
|
+44.28% |
| 5 Year |
|
-5.15% |
| 10 Year |
|
+289.27% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -1.58 | 14.28 | 17.96 | 16.87 | 12.97 | 13.02 | 11.09 | 8.21 | -1.21 | |
| Return on Capital Employed (%) | 5.72 | 12.42 | 14.44 | 15.21 | 13.06 | 12.2 | 12.02 | 9.97 | 2.53 | |
| Return on Assets (%) | -0.46 | 4.46 | 6.52 | 6.91 | 5.55 | 5.74 | 5.45 | 4.44 | -0.63 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 2,454 | 2,966 | 3,436 | 4,087 | 4,809 | 5,604 | 4,741 | 5,319 | 5,399 | 5,410 | |
| Non Curr. Liab. | 4,036 | 3,347 | 3,826 | 3,417 | 4,420 | 4,088 | 2,973 | 2,922 | 3,765 | 3,974 | |
| Curr. Liab. | 2,129 | 2,464 | 1,684 | 2,005 | 2,090 | 2,619 | 1,049 | 1,592 | 1,772 | 1,790 | |
| Minority Int. | -38 | -47 | -52 | 0 | 0 | -2 | -7 | -9 | |||
| Equity & Liab. | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,166 | |
| Non Curr. Assets | 5,904 | 5,864 | 5,951 | 6,267 | 6,734 | 7,272 | 5,811 | 6,320 | 7,167 | 7,559 | |
| Curr. Assets | 2,715 | 2,875 | 2,948 | 3,190 | 4,585 | 5,038 | 2,953 | 3,509 | 3,762 | 3,606 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,166 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 5,826 | 5,749 | 5,861 | 7,518 | 9,111 | 5,976 | 6,099 | 6,130 | 6,282 | 6,622 | |
| Other Income | 42 | 13 | 25 | 40 | 36 | 37 | 18 | 11 | 38 | 59 | |
| Total Income | 5,869 | 5,763 | 5,886 | 7,558 | 9,147 | 6,013 | 6,116 | 6,141 | 6,320 | 6,681 | |
| Total Expenditure | -5,125 | -4,502 | -4,516 | -5,999 | -7,372 | -4,428 | -4,702 | -4,974 | -5,505 | -5,774 | |
| PBIDT | 744 | 1,260 | 1,370 | 1,558 | 1,775 | 1,585 | 1,414 | 1,168 | 815 | 907 | |
| Interest | -368 | -371 | -341 | -284 | -220 | -200 | -184 | -145 | -188 | -255 | |
| Depreciation | -288 | -347 | -291 | -415 | -371 | -340 | -349 | -382 | -554 | -552 | |
| Taxation | -80 | -155 | -163 | -225 | -327 | -335 | -297 | -217 | -93 | -104 | |
| Exceptional Items | -48 | -280 | -33 | -21 | -57 | ||||||
| PAT | -40 | 387 | 575 | 634 | 577 | 678 | 574 | 413 | -65 | -3 | |
| Minority Interest | -18 | 5 | 1 | 8 | -3 | 0 | 1 | 4 | 4 | ||
| Share Associate | 37 | ||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | -58 | 392 | 576 | 643 | 574 | 898 | 836 | 414 | -61 | 38 | |
| Adjusted EPS | -4 | 25 | 37 | 41 | 36 | 56 | 53 | 26 | -4 | 2 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 772 | 783 | 1,099 | 1,268 | 1,303 | 1,122 | 1,543 | 1,784 | 838 | 661 | |
| Cash Fr. Inv. | -174 | -343 | -313 | -450 | -618 | -1,012 | -327 | -739 | -380 | -544 | |
| Cash Fr. Finan. | -414 | -503 | -843 | -686 | -901 | 657 | -1,050 | -1,709 | -33 | -157 | |
| Net Change | 183 | -63 | -56 | 132 | -216 | 767 | 166 | -664 | 425 | -40 | |
| Cash & Cash Eqvt | 473 | 392 | 339 | 456 | 244 | 1,005 | 1,231 | 502 | 984 | 1,014 |
|
Thu, 18 Apr 2024
Closure Of Manufacturing Operations Of Solid Dosage Formulation Facility Of Jubilant Cadista Pharmaceuticals Inc. USA ('Jubilant Cadista') A Subsidiary Located At Salisbury Maryland USA. Further Following The Status Change Of Jubilant Generics Limited'S ('JGL') Roorkee Facility By USFDA To VAI The Company Expects The Exports From The Roorkee Facility To The US Market To Increase In A Meaningful And Gradual Manner. Closure of manufacturing operations of Solid dosage formulation facility of Jubilant Cadista Pharmaceuticals Inc. USA |
|
Wed, 17 Apr 2024
USFDA Communication USFDA Communication - Roorkee Facility |
|
Wed, 10 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Intimation under Reg. 74(5) of the SEBI (DP) Regulations 2018 |
| Fri, 19 Apr 2024 |
Higher Trade Quantity
|
Opening at High
|
Closing Below Previous Low
|
Close Within 52 Week High Zone
|
High Increase in 1 Month
|
